文献速递眼底病与葡萄膜炎

APEX II期随机试验:口服X-82治疗渗出性年龄相关性黄斑变性的安全性与初步疗效

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration.
PubMed 文献 · Br J Ophthalmol · 2020-06-25

APEX是一项II期随机双盲安慰剂对照试验,纳入157例既往接受过至少两次抗VEGF注射的渗出性AMD患者,随机接受每日50mg、100mg、200mg X-82或安慰剂。因胃肠道和肝胆不良事件及主要终点已达到,试验在第二次中期分析后提前终止;所有X-82组视力非劣效于安慰剂(p<0.001),52周注射次数呈剂量依赖性减少,但X-82耐受性和安全性有限,获益风险比不足。

要点

  • X-82所有剂量组视力非劣效于安慰剂(p<0.001)。
  • 52周抗VEGF注射次数呈剂量依赖性减少,50mg组6.7次、100mg组6.0次、200mg组4.7次、安慰剂组8.1次。
  • 因胃肠道和肝胆不良事件及主要终点达到,试验提前终止,X-82获益风险比不足。

核心结论

  • X-82口服联合按需抗VEGF注射在视力结局上非劣效于安慰剂,并呈剂量依赖性减少抗VEGF注射次数。
  • 鉴于耐受性和安全性问题有限,X-82在AMD治疗中获益风险比不足。

研究设计与样本

  • II期随机、双盲、安慰剂对照试验,纳入既往诊断渗出性AMD且接受过至少两次抗VEGF注射的受试者。
  • 受试者等量随机分为四组,分别接受每日50mg、100mg或200mg X-82或安慰剂片剂。
  • 每4周随访一次至52周,评估是否需要抗VEGF救援治疗;共纳入157例患者。

主要发现

  • 主要终点视力非劣效于安慰剂在所有X-82组均达到(p<0.001)。
  • 52周内注射次数呈剂量依赖性趋势:50mg组(n=40)6.7次、100mg组(n=39)6.0次、200mg组(n=39)4.7次、安慰剂组(n=39)8.1次。
  • 因胃肠道和肝胆不良事件及主要终点达到,试验在第二次中期分析后提前终止。

关键数值与推荐

  • 主要终点为非劣效性视力比较,所有X-82组与安慰剂相比p<0.001。
  • 52周注射次数:50mg组6.7次、100mg组6.0次、200mg组4.7次、安慰剂组8.1次。

临床怎么用

  • X-82联合按需抗VEGF注射可减少注射次数,但因耐受性和安全性问题,不推荐用于AMD治疗。

局限性

  • 试验因胃肠道和肝胆不良事件及主要终点达到而提前终止。
  • 原文指出X-82耐受性和安全性问题有限,获益风险比不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The safety and efficacy of X-82, an orally administered inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor, was investigated for treatment of wet age-related macular degeneration (AMD) in a phase II clinical trial. METHODS: This phase II, randomised, double-masked, placebo-controlled trial enrolled subjects with a prior diagnosis of exudative AMD having received at least two intravitreal injections of anti-VEGF therapy. Subjects were randomised equally into four groups that received either daily 50mg, 100mg or 200mg dosages of X-82 or a placebo tablet. At each 4-week interval visit for 52 weeks, subjects were to be assessed to determine if rescue treatment was needed with anti-VEGF therapy. RESULTS: 157 patients were enrolled. Due to gastrointestinal and hepatobiliary adverse events and the fulfilment of the primary endpoint, the trial was stopped prematurely after a second interim analysis. The primary endpoint of non-inferiority of visual acuity compared with placebo was demonstrated in all groups receiving X-82 (p<0.001). There was a dose-dependent trend in the number of injections over a 52-week period, with the 50 mg (n=40), 100 mg (n=39), 200 mg (n=39) and placebo (n=39) group requiring 6.7, 6.0, 4.7 and 8.1 injections, respectively. CONCLUSIONS: X-82 oral therapy in combination with pro re nata anti-VEGF injections showed non-inferiority in visual acuity outcomes while achieving a dose-dependent decrease in the number of anti-VEGF injections compared with placebo. Given the limited tolerability and safety issues observed, X-82 does not have a sufficient benefit to risk profile in treatment of patients with AMD.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cohen MN, O'Shaughnessy D, Fisher K, et al. APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration. Br J Ophthalmol. 2020. PMID: 32586932. doi:10.1136/bjophthalmol-2020-316511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。